Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer

Bradley J. Stish, Thomas M. Pisansky, William S. Harmsen, Brian J. Davis, Katherine S. Tzou, Richard Choo, Steven J. Buskirk

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Purpose To describe outcomes of salvage radiotherapy (SRT) for men with detectable prostate-specific antigen (PSA) after radical prostatectomy for prostate cancer and identify associations with outcomes. Patients and Methods A total of 1,106 patients received SRT between January 1987 and July 2013, with median follow-up 8.9 years. Outcomes were estimated using Kaplan-Meier for overall survival (OS) and cumulative incidence for biochemical recurrence (BcR), distant metastases (DM), and cause-specific mortality (CSM). Variable associations with outcomes used Cox or Fine-Gray methods, as appropriate. Multiple variable analyses used backward selection with P < .05 for retention. Results In multiple variable analyses, pathologic tumor stage, Gleason score, and pre-SRT PSA were associated with BcR, DM, CSM, and OS; androgen suppression and SRT doses > 68 Gy were associated with BcR; and age was associated with OS. Each pre-SRT PSA doubling increased significantly the relative risk of BcR (hazard ratio [HR], 1.30; P≤.001), DM(HR, 1.32; P≤.001), CSM (HR, 1.40; P , .001), and all-cause mortality (HR, 1.12; P = .02). Using a pre-SRT PSA cutoff ≤ 0.5 versus > 0.5 ng/mL, 5-year and 10-year cumulative incidences for BcR were 42% versus 56% and 60% versus 68% (P < .001), DM 7% versus 14% and 13% versus 25% (P < .001), CSM 1% versus 4% and 6% versus 13% (P < .001), and OS of 94% versus 92% and 83% versus 73% (P > .05). Conclusion SRT outcomes are in part affected by factors associated with prostatectomy findings but may be positively affected by using SRT at lower PSA levels, including reductions in BcR, DM, CSM, and allcause mortality. These findings argue against prolonged monitoring of detectable postprostatectomy PSA levels that delay initiation of SRT.

Original languageEnglish (US)
Pages (from-to)3864-3871
Number of pages8
JournalJournal of Clinical Oncology
Volume34
Issue number32
DOIs
StatePublished - Nov 10 2016

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms
Radiotherapy
Neoplasm Metastasis
Survival
Recurrence
Mortality
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. / Stish, Bradley J.; Pisansky, Thomas M.; Harmsen, William S.; Davis, Brian J.; Tzou, Katherine S.; Choo, Richard; Buskirk, Steven J.

In: Journal of Clinical Oncology, Vol. 34, No. 32, 10.11.2016, p. 3864-3871.

Research output: Contribution to journalArticle

Stish, Bradley J. ; Pisansky, Thomas M. ; Harmsen, William S. ; Davis, Brian J. ; Tzou, Katherine S. ; Choo, Richard ; Buskirk, Steven J. / Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 32. pp. 3864-3871.
@article{02c7134be21b4a2281f458345b768513,
title = "Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer",
abstract = "Purpose To describe outcomes of salvage radiotherapy (SRT) for men with detectable prostate-specific antigen (PSA) after radical prostatectomy for prostate cancer and identify associations with outcomes. Patients and Methods A total of 1,106 patients received SRT between January 1987 and July 2013, with median follow-up 8.9 years. Outcomes were estimated using Kaplan-Meier for overall survival (OS) and cumulative incidence for biochemical recurrence (BcR), distant metastases (DM), and cause-specific mortality (CSM). Variable associations with outcomes used Cox or Fine-Gray methods, as appropriate. Multiple variable analyses used backward selection with P < .05 for retention. Results In multiple variable analyses, pathologic tumor stage, Gleason score, and pre-SRT PSA were associated with BcR, DM, CSM, and OS; androgen suppression and SRT doses > 68 Gy were associated with BcR; and age was associated with OS. Each pre-SRT PSA doubling increased significantly the relative risk of BcR (hazard ratio [HR], 1.30; P≤.001), DM(HR, 1.32; P≤.001), CSM (HR, 1.40; P , .001), and all-cause mortality (HR, 1.12; P = .02). Using a pre-SRT PSA cutoff ≤ 0.5 versus > 0.5 ng/mL, 5-year and 10-year cumulative incidences for BcR were 42{\%} versus 56{\%} and 60{\%} versus 68{\%} (P < .001), DM 7{\%} versus 14{\%} and 13{\%} versus 25{\%} (P < .001), CSM 1{\%} versus 4{\%} and 6{\%} versus 13{\%} (P < .001), and OS of 94{\%} versus 92{\%} and 83{\%} versus 73{\%} (P > .05). Conclusion SRT outcomes are in part affected by factors associated with prostatectomy findings but may be positively affected by using SRT at lower PSA levels, including reductions in BcR, DM, CSM, and allcause mortality. These findings argue against prolonged monitoring of detectable postprostatectomy PSA levels that delay initiation of SRT.",
author = "Stish, {Bradley J.} and Pisansky, {Thomas M.} and Harmsen, {William S.} and Davis, {Brian J.} and Tzou, {Katherine S.} and Richard Choo and Buskirk, {Steven J.}",
year = "2016",
month = "11",
day = "10",
doi = "10.1200/JCO.2016.68.3425",
language = "English (US)",
volume = "34",
pages = "3864--3871",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "32",

}

TY - JOUR

T1 - Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer

AU - Stish, Bradley J.

AU - Pisansky, Thomas M.

AU - Harmsen, William S.

AU - Davis, Brian J.

AU - Tzou, Katherine S.

AU - Choo, Richard

AU - Buskirk, Steven J.

PY - 2016/11/10

Y1 - 2016/11/10

N2 - Purpose To describe outcomes of salvage radiotherapy (SRT) for men with detectable prostate-specific antigen (PSA) after radical prostatectomy for prostate cancer and identify associations with outcomes. Patients and Methods A total of 1,106 patients received SRT between January 1987 and July 2013, with median follow-up 8.9 years. Outcomes were estimated using Kaplan-Meier for overall survival (OS) and cumulative incidence for biochemical recurrence (BcR), distant metastases (DM), and cause-specific mortality (CSM). Variable associations with outcomes used Cox or Fine-Gray methods, as appropriate. Multiple variable analyses used backward selection with P < .05 for retention. Results In multiple variable analyses, pathologic tumor stage, Gleason score, and pre-SRT PSA were associated with BcR, DM, CSM, and OS; androgen suppression and SRT doses > 68 Gy were associated with BcR; and age was associated with OS. Each pre-SRT PSA doubling increased significantly the relative risk of BcR (hazard ratio [HR], 1.30; P≤.001), DM(HR, 1.32; P≤.001), CSM (HR, 1.40; P , .001), and all-cause mortality (HR, 1.12; P = .02). Using a pre-SRT PSA cutoff ≤ 0.5 versus > 0.5 ng/mL, 5-year and 10-year cumulative incidences for BcR were 42% versus 56% and 60% versus 68% (P < .001), DM 7% versus 14% and 13% versus 25% (P < .001), CSM 1% versus 4% and 6% versus 13% (P < .001), and OS of 94% versus 92% and 83% versus 73% (P > .05). Conclusion SRT outcomes are in part affected by factors associated with prostatectomy findings but may be positively affected by using SRT at lower PSA levels, including reductions in BcR, DM, CSM, and allcause mortality. These findings argue against prolonged monitoring of detectable postprostatectomy PSA levels that delay initiation of SRT.

AB - Purpose To describe outcomes of salvage radiotherapy (SRT) for men with detectable prostate-specific antigen (PSA) after radical prostatectomy for prostate cancer and identify associations with outcomes. Patients and Methods A total of 1,106 patients received SRT between January 1987 and July 2013, with median follow-up 8.9 years. Outcomes were estimated using Kaplan-Meier for overall survival (OS) and cumulative incidence for biochemical recurrence (BcR), distant metastases (DM), and cause-specific mortality (CSM). Variable associations with outcomes used Cox or Fine-Gray methods, as appropriate. Multiple variable analyses used backward selection with P < .05 for retention. Results In multiple variable analyses, pathologic tumor stage, Gleason score, and pre-SRT PSA were associated with BcR, DM, CSM, and OS; androgen suppression and SRT doses > 68 Gy were associated with BcR; and age was associated with OS. Each pre-SRT PSA doubling increased significantly the relative risk of BcR (hazard ratio [HR], 1.30; P≤.001), DM(HR, 1.32; P≤.001), CSM (HR, 1.40; P , .001), and all-cause mortality (HR, 1.12; P = .02). Using a pre-SRT PSA cutoff ≤ 0.5 versus > 0.5 ng/mL, 5-year and 10-year cumulative incidences for BcR were 42% versus 56% and 60% versus 68% (P < .001), DM 7% versus 14% and 13% versus 25% (P < .001), CSM 1% versus 4% and 6% versus 13% (P < .001), and OS of 94% versus 92% and 83% versus 73% (P > .05). Conclusion SRT outcomes are in part affected by factors associated with prostatectomy findings but may be positively affected by using SRT at lower PSA levels, including reductions in BcR, DM, CSM, and allcause mortality. These findings argue against prolonged monitoring of detectable postprostatectomy PSA levels that delay initiation of SRT.

UR - http://www.scopus.com/inward/record.url?scp=84995389707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995389707&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.68.3425

DO - 10.1200/JCO.2016.68.3425

M3 - Article

VL - 34

SP - 3864

EP - 3871

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 32

ER -